GOCOVRI

214 rs, Gocovri is a brand name for the medication amantadine extended-release capsules. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of dyskinesia, a side effect associated with long-term use of levodopa therapy in individuals with Parkinson's disease. Dyskinesia refers to involuntary, uncontrollable movements that can occur in individuals with Parkinson's disease, particularly as a result of long-term use of levodopa, the main medication used to manage Parkinson's symptoms. Gocovri contains amantadine, which is thought to work by regulating the release of certain neurotransmitters in the brain, including dopamine. By modulating dopamine levels, Gocovri helps reduce dyskinesia and improve motor control in individuals with Parkinson's disease.